Cambridge, United Kingdom
AstraZeneca is a leading player in the biopharmaceutical industry, dedicated to offering innovative solutions for major global diseases. Operating under the slogan "Biopharmaceutical solutions for major global diseases," the company is committed to transforming healthcare by harnessing scientific advancements for the benefit of people, society, and the planet.
Founded in 1913 and headquartered in the United Kingdom, AstraZeneca has established a long-standing reputation in the healthcare sector. The company's recent funding activity includes a $2.00B Post-Ipo Debt investment dated February 1, 2026, marking a significant milestone in their financial strategy. The specific investors of this round were not disclosed. Despite over a century in operation, AstraZeneca continues to pursue aggressive growth and innovation, making it a potentially attractive opportunity for investors looking to partake in long-term value creation within the biopharmaceutical landscape.
